Monitor SYMON-II enrollment completion (750 patients) as the next catalyst for 510(k) submission timing. At the current burn rate of ~$1.9M/quarter, cash runway extends only ~2 quarters, increasing the likelihood of a dilutive offering.
Price Chart
Executive Summary
Bluejay Diagnostics reported Q1 2026 results with cash of $3.7M and a net loss of $1.9M, unchanged YoY. The company provided operational updates on its Symphony IL-6 sepsis test, including SYMON-II trial enrollment at ~680 of 750 patients and manufacturing progress with Sanyoseiko. There is no revenue or EPS, and guidance was not provided.
Key Facts
- Cash and cash equivalents of $3.7M as of March 31, 2026
- Net loss of $1.9M for Q1 2026, unchanged from Q1 2025
- SYMON-II pivotal study enrollment at ~680 patients toward 750 target
- Manufacturing issues resolved for Symphony cartridges; progressing toward analytical/clinical validation
- Company maintains objective of future 510(k) submission for Symphony IL-6
Financial Impact
No revenue; net loss unchanged YoY at $1.9M per quarter
Risk Factors
- Cash runway of ~2 quarters at current burn rate, requiring additional financing
- No revenue or regulatory clearance; clinical/regulatory delays could impair stock
- Potential dilution from future capital raises given $2M market cap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-053295 |
| Document: ea028958001ex99-1.htm | 0001213900-26-053295 |
| Document: 0001213900-26-053295-index-headers.html | 0001213900-26-053295 |
| Document: 0001213900-26-053295-index.html | 0001213900-26-053295 |
| Document: 0001213900-26-053295.txt | 0001213900-26-053295 |
| 8-K Data (Synthetic) | 0001213900-26-053295 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | $0.8323 | awaiting T+20 | — | $0.5770 (−30.67%) |
Oct 6, 2026 21d ago | 8-K | $0.8107 | awaiting T+20 | — | $0.5770 (−28.83%) |
Aug 13, 2026 10w ago | 8-K | $1.06 | awaiting T+20 | — | $0.5770 (−45.57%) |
Aug 13, 2026 10w ago | Press Release | $1.06 | awaiting T+20 | — | $0.5770 (−45.57%) |
Jul 22, 2026 13w ago | 8-K | $1.14 $0.9393 | ▼ −17.61% | ▼ −20.91% | $0.5770 (−49.39%) |
Jul 13, 2026 15w ago | 3 | $1.22 $0.9872 | ▼ −19.08% | ▼ −22.27% | $0.5770 (−52.70%) |
Jul 10, 2026 15w ago | 3 | $1.45 $1.07 | ▼ −26.21% | ▼ −28.63% | $0.5770 (−60.21%) |
Jun 29, 2026 17w ago | EFFECT | $1.44 $1.03 | ▲ +28.47% | ▲ +28.19% | $0.5770 (+59.93%) |
Jun 17, 2026 18w ago | S-3 | $4.46 $1.30 | ▲ +70.85% | ▲ +71.39% | $0.5770 (+87.06%) |
Jun 9, 2026 20w ago | 8-K | $4.49 $1.40 | ▼ −68.82% | ▼ −72.44% | $0.5770 (−87.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers